We provide you with 20 years of free, institutional-grade data for JANX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of JANX. Explore the full financial landscape of JANX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Gujrathi Sheila | Grant, award...etc | 3,750 | 2025-06-13 | ||
| Hernday Natasha | Grant, award...etc | 3,750 | 2025-06-13 | ||
| McNulty Alana B. | Grant, award...etc | 3,750 | 2025-06-13 | ||
| Simson Jake | Grant, award...etc | 3,750 | 2025-06-13 | ||
| Kung Winston | Grant, award...etc | 3,750 | 2025-06-13 | ||
| DOBMEIER ERIC | Grant, award...etc | 3,750 | 2025-06-13 | ||
| RA CAPITAL MANAGEMENT, L.P. | Grant, award...etc | 3,750 | 2025-06-13 | ||
| CAPPS VICKIE L | Grant, award...etc | 3,750 | 2025-06-13 | ||
| Barrett Ronald W | Grant, award...etc | 3,750 | 2025-06-13 | ||
| Doyle Janeen Noel | Grant, award...etc | 44,000 | 2025-06-04 | ||
| Meyer Andrew Hollman | Sale | -3,333 | $31.95 | $106,482 | 2025-05-02 |
| Meyer Andrew Hollman | Derivatives Exercise | 3,333 | 2025-05-02 | ||
| Meyer Andrew Hollman | Sale | -3,334 | $30 | $100,020 | 2025-04-23 |
| Meyer Andrew Hollman | Derivatives Exercise | 3,334 | 2025-04-23 | ||
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 824,041 | $30.56 | 2025-03-07 | |
| Meyer Andrew Hollman | Sale | -3,334 | $31.88 | $106,304 | 2025-03-05 |
| Meyer Andrew Hollman | Derivatives Exercise | 3,334 | 2025-03-05 | ||
| Meyer Andrew Hollman | Sale | -3,334 | $42.08 | $140,280 | 2025-02-05 |
| Meyer Andrew Hollman | Derivatives Exercise | 3,334 | 2025-02-05 | ||
| Campbell David Alan | Sale | -5,000 | $60 | $300,004 | 2025-01-08 |
| Dobek Maria | Grant, award...etc | 14,000 | 2025-01-03 | ||
| DiRaimondo Thomas | Grant, award...etc | 24,000 | 2025-01-03 | ||
| Meyer Andrew Hollman | Sale | -13,334 | $53.76 | $716,812 | 2025-01-03 |
| Meyer Andrew Hollman | Grant, award...etc | 18,000 | 2025-01-03 | ||
| Robinson Byron | Grant, award...etc | 28,000 | 2025-01-03 | ||
| Winter Charles M. | Grant, award...etc | 23,000 | 2025-01-03 | ||
| McIver Zachariah | Grant, award...etc | 26,000 | 2025-01-03 | ||
| Campbell David Alan | Grant, award...etc | 81,000 | 2025-01-03 | ||
| Campbell David Alan | Sale | -25,000 | $56.19 | $1,404,805 | 2024-12-27 |
| Meyer Andrew Hollman | Derivatives Exercise | 9,881 | 2024-12-20 | ||
| Campbell David Alan | Sale | -15,000 | $67 | $1,005,000 | 2024-12-03 |
| Campbell David Alan | Sale | -25,000 | $51.43 | $1,285,805 | 2024-11-27 |
| Campbell David Alan | Sale | -25,000 | $53.22 | $1,330,593 | 2024-10-30 |
| Lichter Jay | Sale | -3,815 | $46.68 | $178,084 | 2024-10-24 |
| Lichter Jay | Derivatives Exercise | 3,815 | 2024-10-24 | ||
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 1,200,000 | $44.75 | 2024-10-22 | |
| Avalon Ventures XI, L.P. | Sale | -765,438 | $49.69 | $38,034,614 | 2024-10-18 |
| Avalon Ventures XI, L.P. | Sale | -145,219 | $49.69 | $7,215,932 | 2024-10-18 |
| Avalon Ventures XI, L.P. | Derivatives Exercise | 12,284 | 2024-10-18 | ||
| Avalon Ventures XI, L.P. | Sale | -762,471 | $49.69 | $37,887,184 | 2024-10-18 |
| Avalon Ventures XI, L.P. | Sale | -140,603 | $46.78 | $6,577,408 | 2024-09-30 |
| Avalon Ventures XI, L.P. | Sale | -26,687 | $46.78 | $1,248,418 | 2024-09-30 |
| Avalon Ventures XI, L.P. | Derivatives Exercise | 2,671 | 2024-09-30 | ||
| Avalon Ventures XI, L.P. | Sale | -140,489 | $46.78 | $6,572,075 | 2024-09-30 |
| DiRaimondo Thomas | Sale | -5,000 | $46.21 | $231,029 | 2024-09-27 |
| Campbell David Alan | Sale | -25,000 | $46.09 | $1,152,233 | 2024-09-27 |
| Meyer Andrew Hollman | Sale | -50,000 | $45.96 | $2,297,755 | 2024-09-27 |
| Meyer Andrew Hollman | Derivatives Exercise | 50,000 | 2024-09-27 | ||
| Avalon Ventures XI, L.P. | Sale | -207,960 | $46.13 | $9,593,195 | 2024-09-12 |
| Avalon Ventures XI, L.P. | Sale | -39,455 | $46.13 | $1,820,059 | 2024-09-12 |
| Avalon Ventures XI, L.P. | Sale | -203,676 | $46.13 | $9,395,574 | 2024-09-12 |
| Avalon Ventures XI, L.P. | Sale | -110,644 | $42 | $4,647,048 | 2024-09-10 |
| Avalon Ventures XI, L.P. | Sale | -20,991 | $42 | $881,622 | 2024-09-10 |
| Avalon Ventures XI, L.P. | Derivatives Exercise | 2,099 | 2024-09-10 | ||
| Avalon Ventures XI, L.P. | Sale | -110,547 | $42 | $4,642,974 | 2024-09-10 |
| DOBMEIER ERIC | Grant, award...etc | 1,231 | 2024-07-24 | ||
| Hernday Natasha | Grant, award...etc | 1,231 | 2024-07-24 | ||
| Hernday Natasha | Grant, award...etc | 7,500 | 2024-07-22 | ||
| DOBMEIER ERIC | Grant, award...etc | 7,500 | 2024-07-22 | ||
| Lichter Jay | Grant, award...etc | 2,500 | 2024-06-28 | ||
| Simson Jake | Grant, award...etc | 2,500 | 2024-06-28 | ||
| Gujrathi Sheila | Grant, award...etc | 2,500 | 2024-06-28 | ||
| Barrett Ronald W | Grant, award...etc | 2,500 | 2024-06-28 | ||
| CAPPS VICKIE L | Grant, award...etc | 2,500 | 2024-06-28 | ||
| RA CAPITAL MANAGEMENT, L.P. | Grant, award...etc | 2,500 | 2024-06-28 | ||
| Kung Winston | Grant, award...etc | 2,500 | 2024-06-28 | ||
| McNulty Alana B. | Grant, award...etc | 2,500 | 2024-06-28 | ||
| Avalon Ventures XI, L.P. | Sale | -691,525 | $54.75 | $37,860,994 | 2024-06-05 |
| Avalon Ventures XI, L.P. | Sale | -131,196 | $54.75 | $7,182,981 | 2024-06-05 |
| Avalon Ventures XI, L.P. | Sale | -677,279 | $54.75 | $37,081,025 | 2024-06-05 |
| Lichter Jay | Sale | -691,525 | $54.75 | $37,860,994 | 2024-06-05 |
| Lichter Jay | Sale | -131,196 | $54.75 | $7,182,981 | 2024-06-05 |
| Lichter Jay | Sale | -677,279 | $54.75 | $37,081,025 | 2024-06-05 |
| Reardon Tighe | Sale | -691,525 | $54.75 | $37,860,994 | 2024-06-05 |
| Reardon Tighe | Sale | -131,196 | $54.75 | $7,182,981 | 2024-06-05 |
The information provided in this report about JANX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Janux Therapeutics(NASDAQ:JANX) 
Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering f...
Website: https://www.januxrx.com/
Founded: 2017
IPO Price: $17 (Jun 11, 2021)
CEO: David Campbell
Sector:
Industry:
Share this website to your friends